# OnCo record pamidronate (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/pamidronate/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "pamidronate" ;
  schema:name "Pamidronate"@en ;
  schema:description "Pamidronate (Aredia) is a bisphosphonate infusion approved in 1991 for dangerously high blood calcium in cancer and later for bone damage from myeloma and breast cancer, where it roughly halved skeletal complications. Its two-hour infusion, against fifteen minutes for zoledronic acid, pushed most centres to switch, though it is cheaper and may cause less jaw osteonecrosis."@en ;
  schema:url <https://onco.cc/drugs/pamidronate/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Pamidronic_acid> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=pamidronate>, <https://www.cancer.gov/about-cancer/treatment/drugs/pamidronatedisodium> ;
  onco:status "approved" ;
  onco:tag "nci-list", "generic", "supportive" ;
  onco:modality "Nitrogen-containing bisphosphonate (intravenous)" ;
  schema:alternateName "Aredia (historic)" ;
  onco:approval "US 1991: Hypercalcaemia of malignancy", "US 1995: Osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma, with antineoplastic therapy" ;
  onco:related <https://onco.cc/drugs/zoledronic-acid/>, <https://onco.cc/drugs/denosumab/> ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:technologies <https://onco.cc/technologies/bone-modifying-agents/> ;
  onco:companies <https://onco.cc/companies/novartis/> ;
  onco:trials <https://onco.cc/trials/nct00376883/>, <https://onco.cc/trials/nct00033332/>, <https://onco.cc/trials/nct00083382/> .